In a decision announced today (March 26), the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (USPTO and PTAB, respectively) reaffirmed its original decision that the Broad Institute, ...
CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double ...
Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...
In a decision released today (May 12), the U. S. Court of Appeals for the Federal Circuit in Washington, D.C., ordered the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) to ...
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...
Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein ...
Since the landmark discovery that a bacterial defense mechanism could be repurposed into programmable “molecular scissors,” CRISPR-Cas9 gene-editing technology has undergone a major evolution. Over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results